A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Results
  • Discussion
  • Disclosures
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

This animal model enables researchers to induce statistically significant secondary lymphedema in the hindlimb of mice, lasting at least 8 weeks. The model can be used to study the pathophysiology of lymphedema and to investigate novel treatment options.

Abstract

Animal models are of paramount importance in the research of lymphedema in order to understand the pathophysiology of the disease but also to explore potential treatment options. This mouse model allows researchers to induce significant lymphedema lasting at least 8 weeks. Lymphedema is induced using a combination of fractioned radiotherapy and surgical ablation of lymphatics. This model requires that the mice get a dose of 10 Gray (Gy) radiation before and after surgery. The surgical part of the model involves ligation of three lymph vessels and extraction of two lymph nodes from the mouse hindlimb. Having access to microsurgical tools and a microscope is essential, due to the small anatomical structures of mice. The advantage of this model is that it results in statistically significant lymphedema, which provides a good basis for evaluating different treatment options. It is also a great and easily available option for microsurgical training. The limitation of this model is that the procedure can be time consuming, especially if not practiced in advance. The model results in objectively quantifiable lymphedema in mice, without causing severe morbidity and has been tested in three separate projects.

Introduction

Lymphedema is characterized by an accumulation of lymph fluid that leads to localized tissue swelling, which mainly occurs due to impaired or disrupted flow of lymph fluid in the lymphatic vessels1. The lymph flow can be impaired or disrupted by infection, obstruction, injury or congenital defects in the lymphatic system2. These etiologies result in accumulation of lymphatic fluid, which leads to a chronic state of inflammation, resulting in subsequent fibrosis, as well as deposition of adipose tissue3. Lymphedema can be categorized as primary or secondary lymphedema. Primary lymphedema is caused by developmental abnormalities or genetic mutation2,4. Secondary lymphedema occurs due to underlying systemic disease, surgery or trauma2,4. Secondary lymphedema is the most common form of lymphedema in the world2. In developed countries, the most common cause of secondary lymphedema is oncological therapy such as adjuvant radiotherapy and lymph node dissection5. Lymphedema is most frequent among breast cancer patients, but can also develop in patients with gynecologic, melanoma, genitourinary or neck cancer6. It has been suggested that out of all women diagnosed with breast cancer, 21% will develop lymphedema7.

Lymphedema can be stressful to the patient both physically and psychologically. Patients with lymphedema have an increased risk of infection5,8,9, poor quality of life and can develop social anxiety and symptoms of depression10. The complications of chronic lymphedema lead to high cost of care and an increased disease burden9,11. Findings have also suggested that lymphedema might be associated with increased risk of death after breast cancer treatment12. Conservative management such as compression of the affected area, manual lymph drainage and general skincare remain the first line approach. There is currently no curative treatment6. Although progress has been made in the field of surgical and medical therapy, there is still room for improvement. More research, providing insight in the pathophysiology and progression of the disease, is needed to enable clinicians to provide better treatment options for the patients5.

Animal models are being used in preclinical research to understand the pathophysiology of diseases and develop potential treatment options. Several different lymphedema animal models have been established in canines13,14, rabbits15, sheep16, pigs17,18 and rodents19,20,21,22,23,24. The rodent model seems to be the most cost-effective model, when investigating the reconstruction of lymphatic function, due to rodents being easily accessible and relatively low-priced25. The majority of the mice models have focused on inducing lymphedema in the tail of the mice21,22,23. The tail model is very reliable but the exact surgical technique for inducing lymphedema varies significantly in previous published material. This results in fluctuations in duration and robustness of the developed lymphedema presented in known litterature25. Different techniques are also being used for inducing lymphedema in the hindlimb model and they also yield varying results, but the hindlimb model might be easier to understand from a translational perspective. Previous lymphedema models have been hampered by spontaneous lymphedema resolution and therefore a reproducible and permanent lymphedema model is needed25. Researchers have previously tried to increase the dose of radiation, to prevent the spontaneous lymphedema resolution, but this has often led to subsequent severe morbidity25.

This model results in statistically significant lymphedema, without causing severe morbidity, by combining microsurgery with radiation. The model has been revised from a previous surgical model by adding a dose of irradiation that induces lymphedema, without causing severe morbidity26. It also offers a great opportunity for microsurgical training. Having access to microsurgical equipment and a microscope is necessary, due to the small anatomical structures of the mice. The surgical procedure can be performed when the user has been taught basic microsurgical techniques, such as suturing with microsurgical instruments. The operators that performed this procedure all watched tutorial videos by Acland on the preconditions of microsurgical skills (1981) and basic microsuture technique (1985). We recommend practicing the surgical procedure 8−10 times before using it in research. Practicing the procedure ensures that fewer mistakes are made and that the procedure can be performed more efficiently. When mastered, the surgical procedure can be performed in 45 minutes.

Protocol

Animals were housed in the University of Southern Denmark Animal Care Facility as per institutional guidelines. All procedures involving animal subjects have been approved by The Animal Experiments Inspectorate, Ministry of Environment and Food of Denmark.

1. Pre-surgery irradiation

NOTE: Pre-surgery irradiation takes place 7 days before surgery.

  1. Induce anesthesia.
    1. Place the mouse in an induction box and set the vaporizer to 3% isoflurane with an oxygen flow rate of 0.8−1.2 L/min to induce inhalation anesthesia.
      NOTE: Alternatively, injectable anesthetics can be used but for the short duration of the irradiation inducing inhalation anesthesia was sufficient. For obtaining the results presented in this article, 9-week old female C57BL6 mice were used.
    2. Make sure the mouse is fully anesthetized by tail or paw pinch test.
  2. Position the mouse for irradiation.
    1. If fully sedated, move the mouse from the induction box and place it under the source of radiation in supine position and gently fixate the hind limbs with tape.
      NOTE: The mouse will remain sedated for the short duration of the radiation.
    2. Place a 1.5 mm thick lead pad to ensure that only the area that undergoes surgery (i.e., the circular area with a diameter of 25 mm around the knee) gets irradiated.
  3. Administer a dose of 10 Gy radiation at a dose rate of 5.11 Gy/min (100 kVp, 10 mA).
    CAUTION: Safety precautions must be taken when working with radiation. During this experiment, all irradiation was performed in a radiation insulated room, and the source of radiation was only turned on when all personnel had left and sealed the room.
  4. Place the mouse back in its cage.

2. Equipment setup

NOTE: Surgery should be performed in a room dedicated to surgical procedures. The operative surface must be sterile.

  1. Thoroughly clean all operative surfaces with 70% ethanol. Wear hairnet and coveralls. Use sterile surgical instruments and sterile gloves.
  2. Prepare anesthesia.
    1. Draw up 1 mL of fentanyl (0.315 mg/mL), 1 mL of midazolam (5 mg/mL), and 2 mL of sterile water. Use different syringes and needles for the different components.
    2. Mix fentanyl and sterile water by slowly emptying the syringes into a sterile glass tube. When mixed, add midazolam to complete the working solution.
  3. Prepare analgesia.
    1. Draw up 0.2 mL of buprenorphine (0.3 mg/mL) and 2 mL of saline.
    2. Mix the volumes by slowly emptying the syringes into a sterile glass tube to complete the working solution.
  4. Turn on the microscope and make sure that the lighting is sufficient, and that the microscope is well adjusted for the operator's eyes.
    NOTE: All surgical procedures should be performed under an operating microscope. A magnification range from 4x−25x is sufficient.

3. Preparation

  1. Weigh the mouse pre-surgery by placing the mouse in an empty container on a cleared scale.
  2. Administer anesthetic.
    1. Draw up 0.1 mL of anesthetic per 10 g of mouse bodyweight. Inject the anesthetic subcutaneously as a bolus injection.
    2. Let the mouse rest in a cage with plenty bedding and shelter for approximately 10 min until fully sedated. Examine the anesthetic depth by assessing muscle relaxation and perform paw or tail pinch test.
  3. When fully sedated, shave the hind limb chosen for the procedure using electrical clippers. Make sure to wipe of excess hair.
  4. Turn on the heating device, such as a heating pad and cover it with a surgical cloth.
  5. Set the flow of oxygen to 0.8 L/min and connect it with a nosecone. Use 100% oxygen.
    NOTE: The nosecone is only for oxygen delivery and not anesthesia.
  6. Apply ophthalmic ointment and inject 0.5 mL of saline subcutaneously, preferably in the scruff of the mouse, to prevent hypovolemia during surgery.
  7. Position the mouse for surgery.
    1. Place the mouse on the surgical cloth in supine position. Place the nosecone over the snout.
    2. Fixate the end of the hindlimbs gently with tape to prevent the mouse from shifting during surgery.
    3. Sterilize the skin using alcohol/chlorhexidine or alcohol/povidone iodine.

4. Surgery

NOTE: In this example, the left hind limb (when the mouse is viewed in supine position), has been chosen for the procedure.

  1. Make a circular incision.
    1. Lift the skin with smooth forceps and clip a small opening approximately 5 mm proximal to the popliteal fossa.
    2. Slide sharp scissors into the opening and clip towards the knee so that the incision ends just above the knee. Make sure not to puncture the underlying vessels by lifting the skin with forceps while clipping.
    3. Move the mouse to prone position and continue to clip from the knee towards the popliteal fossa until the circumferential incision is complete.
  2. Dissect the skin below the knee.
    1. Gently blunt dissect the area below the knee to a couple of millimeters above the ankle, by slowly opening and closing the microscissors while lifting the skin with forceps.
    2. Carefully snip remaining visible adhesions using microscissors. Use sterile saline regularly to keep the tissue moist during the whole procedure.
  3. Dissect the skin at the proximal rim of the circumferential incision so that it can be retracted with an elastic retractor.
    NOTE: The retractor allows the operator a better view of the proximal lymph vessel and prevents the proximal rim from shifting during surgery.
  4. While still in prone position, rotate the hindlimb gently and fixate it with tape, so that the ischiatic vein is visible from the most proximal point of the exposed area to the most distal point.
  5. Inject approximately 0.01 mL of Patent Blue V subcutaneously between the second and third toe using a 0.5 mL syringe with a 30 G needle. Gently press the paw a couple of times to distribute the Patent Blue V. Visualize the lymph vessels and lymph node through the microscope as the Patent Blue V fills the lymph vessels.
    NOTE: If the blue color of the lymph vessels fades during the procedure, gently massage the paw to promote uptake, rather than inject more Patent Blue V. Excess use of Patent Blue V may lead to leakage and coloring of the tissue surrounding the lymph vessels which may compromise the procedure.
  6. Locate the important structures: the popliteal lymph node (PLN), the two lymph vessels distal to the lymph node (DLV1 and DLV2), and the one lymph vessel proximal to the lymph node (PLV).
    NOTE: All the lymph vessels can be found adjacent to the ischiatic vein. The proximal lymph vessel is usually found medial to the vein, the two distal lymph vessels are found medial and lateral to the vein. The abbreviations of the structures are used in the accompanying video.
  7. Magnify to clearly visualize the PLV and ligate it with a 10-0 nylon suture using micro-needle holder and microforceps. Press the paw a couple of times to ensure that no Patent Blue V passes proximal to the suture.
    NOTE: Trimming the fat surrounding the lymph vessel may be necessary.
  8. Repeat step 4.7 to ligate the two distal lymph vessels. Press the paw several times to ensure that no Patent Blue V passes proximal to the ligature. If the lymph vessels lie to close to the ischiatic vein, try dissecting even further distally.
    NOTE: In this example, it can be seen that one of the lymph vessels bursts due to the ligature hindering the lymph flow. The lymph vessels will often split from the vein further down.
  9. Remove the popliteal lymph node.
    1. Locate the popliteal lymph node and clip a small hole with microscissors to access it and remove it with microforceps and microscissors.
      NOTE: The lymph node has a smooth pearl-like surface in contrast to the surrounding fat tissue.
    2. To test if the removed tissue is a lymph node, place it in a test tube filled with water.
      NOTE: If the tissue is comprised of fat, the tissue will float. If the tissue is a lymph node, it will sink to the bottom.
  10. Remove the inguinal fat pad and lymph node.
    1. Before removing the inguinal fat pad, use a bipolar coagulator to cauterize the vessels running through the fat.
    2. Resect the inguinal fat pad using microforceps and microscissors. Gently clip the cauterized vessels running through the fat. Then gently resect the fat tissue in the inguinal area.
      NOTE: The lymph node located in the fat is rarely colored by Patent Blue V and can be hard to differentiate from the fat. Removing the fat pad in one piece is the best way to ensure the lymph node has been removed.
  11. Rinse the leg thoroughly with sterile saline and confirm through the microscope that any small hairs and particles has been thoroughly removed from the surgical area to avoid wound contamination and infection. Make sure there is no active bleeding.
  12. Suture the skin edges down to the muscle facia with a 6-0 nylon suture using forceps and needle holder, leaving a gap of 2−3 mm to constrain the superficial lymph flow.
    NOTE: The accompanying video shows an example of finished sutures.
  13. Administer analgesia. Draw up 0.1 mL of analgesia per 30 g of mouse bodyweight. Inject the analgesia subcutaneously as a bolus injection.
  14. Weigh the mouse for post-surgery for comparison.
  15. Place the mouse in a cage in a cabinet heated for recovery.

5. Postoperative care

  1. Give the mice individual cages to recover after surgery with water and food ad libitum.
  2. Administer a bolus subcutaneous dose of 0.02 mL of buprenorphine 3x daily for 3 days for analgesia.
  3. Monitor the animal daily for appropriate wound healing, signs of pain and infection. If signs of infection are present, use antibiotic ointment.

6. Post-surgery irradiation

  1. Three days after surgery, repeat the procedure for pre-surgery irradiation (steps 1.1−1.4).

Results

This procedure has previously been used in three separate experiments. All the experiments were made by different lead investigators who all are co-authors of this article. In all three experiments, great care was taken to adhere to the same procedure as described in this protocol. In all three experiments, secondary lymphedema was induced in one hindlimb while the other hindlimb served as a control. Volumes of the hindlimbs were the primary outcome in all three experiments.

Discussion

There are a few critical steps in this protocol. Firstly, it is important that the researchers take safety precautions when working with radioactivity. Secondly, during the surgical part of this protocol, it is important to start the procedure once the mouse has been anesthetized and finish it without unnecessary breaks. This is important to avoid an excessively long surgical period for the animal and to prevent that the anesthesia loses effect during surgery. It is recommended to only administer one bolus injection of a...

Disclosures

The authors have nothing to disclose.

Acknowledgements

The authors thank Peter Bollen, head of the Biomedical Laboratory for lending the equipment needed to record the footage seen through the microscopes.

Materials

NameCompanyCatalog NumberComments
10-0 Nylon sutureS&T12051-10
6-0 Nylon suture - DafilonB BraunC0933112
Coagulator - ICC 50ERBE
Cotton tipped applicatorsYibon medical co
Dissecting forcepsLawton09-0190
Elastic retractorsOdense University Hospital
Electrical clipperAesculapGT420
Fentanyl 0,315 mg/mlMatrix
Heating pad - PhysioSuiteKent Scientific Corp.
Isoflurane 1000mg AttaneScan Vet
Isoflurane vaporizer - PPVPenlon
Micro jewler forcepsLawton1405-05
Micro Needle holderLawton25679-14
Micro scissorsLawton10128-15
Micro tying forcepsLawton43953-10
Microfine U-40 syringe 0,5mlBD328821
Microlance syringe 25gBD
Microlance syringe 27gBD
Midazolam 5 mg/ml (hameln)Matrix
Needle holder - Circle woodLawton08-0065
Non woven swabsSelefa
Opmi pico microscope F170Zeiss
Patent blue V - 25 mg/mlGuerbet
Scissors - JosephBDRH1630
Siemens INVEON multimodality pre-clinical scannerSiemens pre-clinical solutions
Source of radiation - D3100Gulmay
Stata Statistical Software: Release 15StataCorp LLC
Temgesic - 0,2 mgIndivior
Vet eye ointment - viscotearsBausch & Lomb

References

  1. Lawenda, B. D., Mondry, T. E., Johnstone, P. A. S. Lymphedema: a primer on the identification and management of a chronic condition in oncologic treatment. CA: A Cancer Journal for Clinicians. 59 (1), 8-24 (2009).
  2. Greene, A. K., Greene, A. K., Slavin, S. A., Brorson, H. Epidemiology and morbidity of lymphedema. Lymphedema: Presentation, Diagnosis, and Treatment. , 33-44 (2015).
  3. Hespe, G. E., Nores, G. G., Huang, J. J., Mehrara, B. J. Pathophysiology of lymphedema-Is there a chance for medication treatment?. Journal of Surgical Oncology. 115 (1), 96-98 (2017).
  4. Grada, A. A., Phillips, T. J. Lymphedema: Pathophysiology and clinical manifestations. Journal of the American Academy of Dermatology. 77 (6), 1009-1020 (2017).
  5. Chang, D. W., Masia, J., Garza, R., Skoracki, R., Neligan, P. C. Lymphedema: Surgical and Medical Therapy. Plastic and Reconstructive Surgery. 138 (3 Suppl), 209S-218S (2016).
  6. Carl, H. M., et al. Systematic Review of the Surgical Treatment of Extremity Lymphedema. Journal of Reconstructive Microsurgery. 33 (6), 412-425 (2017).
  7. DiSipio, T., Rye, S., Newman, B., Hayes, S. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. The Lancet Oncology. 14 (6), 500-515 (2013).
  8. Douglass, J., Graves, P., Gordon, S. Self-Care for Management of Secondary Lymphedema: A Systematic Review. PLoS Neglected Tropical Diseases. 10 (6), e0004740 (2016).
  9. Shih, Y. C. T., et al. Incidence, treatment costs, and complications of lymphedema after breast cancer among women of working age: a 2-year follow-up study. Journal of Clinical Oncology. 27 (12), 2007-2014 (2009).
  10. Ridner, S. H. The psycho-social impact of lymphedema. Lymphatic Research and Biology. 7 (2), 109-112 (2009).
  11. Gutknecht, M., et al. Cost-of-illness of patients with lymphoedema. Journal of the European Academy of Dermatology and Venereology. 31 (11), 1930-1935 (2017).
  12. Hayes, S., et al. Prevalence and prognostic significance of secondary lymphedema following breast cancer. Lymphatic Research and Biology. 9 (3), 135-141 (2011).
  13. Danese, C. A., Georgalas-Bertakis, M., Morales, L. E. A model of chronic postsurgical lymphedema in dogs' limbs. Surgery. 64 (4), 814-820 (1968).
  14. Das, S. K., Franklin, J. D., O'Brien, B. M., Morrison, W. A. A practical model of secondary lymphedema in dogs. Plastic and Reconstructive Surgery. 68 (3), 422-428 (1981).
  15. Huang, G. K., Hsin, Y. P. An experimental model for lymphedema in rabbit ear. Microsurgery. 4 (4), 236-242 (1983).
  16. Tobbia, D., et al. Lymphedema development and lymphatic function following lymph node excision in sheep. Journal of Vascular Research. 46 (5), 426-434 (2009).
  17. Lahteenvuo, M., et al. Growth factor therapy and autologous lymph node transfer in lymphedema. Circulation. 123 (6), 613-620 (2011).
  18. Honkonen, K. M., et al. Lymph node transfer and perinodal lymphatic growth factor treatment for lymphedema. Annals of Surgery. 257 (5), 961-967 (2013).
  19. Wang, G. Y., Zhong, S. Z. A model of experimental lymphedema in rats' limbs. Microsurgery. 6 (4), 204-210 (1985).
  20. Oashi, K., et al. A new model of acquired lymphedema in the mouse hind limb: a preliminary report. Annals of Plastic Surgery. 69 (5), 565-568 (2012).
  21. Slavin, S. A., Van den Abbeele, A. D., Losken, A., Swartz, M. A., Jain, R. K. Return of lymphatic function after flap transfer for acute lymphedema. Annals of Surgery. 229 (3), 421-427 (1999).
  22. Cheung, L., et al. An experimental model for the study of lymphedema and its response to therapeutic lymphangiogenesis. BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy. 20 (6), 363-370 (2006).
  23. Rutkowski, J. M., Moya, M., Johannes, J., Goldman, J., Swartz, M. A. Secondary lymphedema in the mouse tail: Lymphatic hyperplasia, VEGF-C upregulation, and the protective role of MMP-9. Microvascular Research. 72 (3), 161-171 (2006).
  24. Tammela, T., et al. Therapeutic differentiation and maturation of lymphatic vessels after lymph node dissection and transplantation. Nature Medicine. 13 (12), 1458-1466 (2007).
  25. Frueh, F. S., et al. Animal models in surgical lymphedema research--a systematic review. Journal of Surgical Research. 200 (1), 208-220 (2016).
  26. Jorgensen, M. G., et al. Quantification of Chronic Lymphedema in a Revised Mouse Model. Annals of Plastic Surgery. 81 (5), 594-603 (2018).
  27. Frueh, F. S., et al. High-resolution 3D volumetry versus conventional measuring techniques for the assessment of experimental lymphedema in the mouse hindlimb. Scientific Reports. 6, 34673 (2016).
  28. Biau, D. J., Kerneis, S., Porcher, R. Statistics in brief: the importance of sample size in the planning and interpretation of medical research. Clinical Orthopaedics and Related Research. 466 (9), 2282-2288 (2008).
  29. Korula, P., Varma, S. K., Sunderrao, S. Inhibition of wound contraction by point-to-point adherent splintage. Plastic and Reconstructive Surgery. 95 (4), 725-730 (1995).
  30. Komatsu, E., et al. Lymph Drainage During Wound Healing in a Hindlimb Lymphedema Mouse Model. Lymphatic Research and Biology. 15 (1), 32-38 (2017).

Reprints and Permissions

Request permission to reuse the text or figures of this JoVE article

Request Permission

Explore More Articles

Secondary LymphedemaHindlimbMiceMicrosurgical TechniquesRadiationAnesthesiaSaline InjectionSurgical ProcedureLead PadIrradiationHypovolemiaIncision TechniqueSciatic VeinPatent Blue V

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2025 MyJoVE Corporation. All rights reserved